Myopia Progression With Freeform Myopia Control Spectacles

Not Applicable

Not yet recruiting

• Conditions: Myopia, Progressive

• Registration Number: NCT06927388
• Lead Sponsor: Shanghai Eye Disease Prevention and Treatment Center

Brief Summary

This is a prospective, randomized clinical trial. There will be a total of 180 participants randomized into three groups, Group 1 - 60 participants will wear the commercial peripheral plus myopia control lens (CML).

Group 2 - 60 participants will wear the Open Ring 1 (OR1) lens design. Group 3 - 60 participants will wear the Open Ring 2 (OR2) lens design. For each group, an equal balance of gender will be recruited and 50% of children will be aged between 6- 9 years old and 50% aged 10-12 years old.

All groups will be required to wear spectacles for all waking hours for 12 months. After 12 months, the control group participants wearing CML will be randomised to wear either OR1 or OR2 lens designs; the Group 2 participants will continue wearing the OR1 lens for a further 12 months. The Group 3 participants will wear OR2 or OR3 (a modified design of OR2) based on their risk of myopia progression for a further 12 months.

Detailed Description

Not available

Study Timeline

• Status Verified: 2025-04
• Study First Submitted: 2025-04-07
• Study First Submitted QC: 2025-04-07
• Last Update Submitted: 2025-04-07
• Study Start: 2025-04-10
• Study First Posted: 2025-04-15
• Last Update Posted: 2025-04-15
• Primary Completion: 2027-09-30
• Study Completion: 2027-09-30

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: All
• Target Recruitment: 180

Inclusion Criteria

Participants enrolled in the trial must:

• be aged between 6 to 12 completed years (6 and 12 years inclusive), irrespective of gender.
• For each group, an equal balance of gender will be recruited and 50% of children will be aged between 6- 9 years old and 50% aged 10-12 years old.
• be cycloplegic autorefraction spherical component -0.50 D to -4.00D, cylinder no more than -1.50D
• be accompanied by parents/guardians who can read and comprehend Chinese and give informed consent as demonstrated by signing a record of informed consent.
• be willing to comply with the wearing and clinical trial visit schedule as directed by the Investigator.
• have ocular health findings considered to be "normal".
• be correctable to at least 6/9.5 (20/30) or better in each eye with spectacles.
• be willing to wear the spectacles provided by the investigators for all waking hours.

Exclusion Criteria

Participants enrolled in the trial must NOT have:

• a known allergy to, or a history of intolerance to tropicamide or topical anaesthetics.
• had strabismus and/or amblyopia.
• Anisometropia greater than 1.50D spherical equivalent
• had previous eye surgery (including strabismus surgery).
• any ocular, systemic or other condition or disease with possible associations with myopia or affecting refractive development e.g. Marfan syndrome, retinopathy of prematurity, diabetes.
• had any ocular injury or condition (including keratoconus and herpes keratitis) of the cornea, conjunctiva or eyelids.
• current orthoptic treatment or vision training.
• any anatomical, skin or other condition that would impact on the wearing of spectacles.
• Use of or a need for concurrent category S3 and above ocular medication at enrolment and/or during the clinical trial.
• Currently enrolled in another clinical trial.
• No previous myopia management intervention or treatment within 3 months of enrolment

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
myopic progression in one year	12 months.	The primary outcome measure of this study is myopic progression in one year. This is expressed as the change in spherical equivalent refractive state from baseline levels. Spherical equivalent refraction will be taken as the mean of the spherical equivalent refraction of five, reliable, cycloplegic autorefraction measurements on each eye. Myopia progression is also expressed as the change in axial length from baseline levels. Myopia progression is characterised by ocular anatomical changes, the most notable being increased axial length. This will be measured at 6 monthly intervals.

Secondary Outcome Measures

Name	Time	Method
myopia progression within myopia risk categories	12 months.	A secondary endpoint is myopia progression within myopia risk categories. Participants risk of progression will be assessed at baseline using variables such as axial length, central refraction, age, parental myopia, gender. Age, axial length percentiles and expected progression, based on published online calculators, will be converted to risk scores and categorised as low medium and high risk.
the wearer subjective experience	12 months.	Another secondary endpoint is the wearer subjective experience which is evaluated using a subjective quality of vision scale for various activities. Both a 1-10 scale (where 1 is poor and 10 is excellent) and a Likert scale will be used and data collected at each study visit.